by Snell, Ashley, "Meta-Analysis of Cannabigerol Effects on Breast Cancer Tissue Cells" (2021). Undergraduate Honors Theses
This is just a simplified version of the theses by Ashely Snell.
CBG shows promising signs as an affective treatment for breast cancer. You can read her full abstract here: https://digscholarship.unco.edu/honors/42
CBG has been brought to the forefront in the cannabinoid research of recent due to its potential benefits concerning human health. The current knowledge is limited in this area as these benefits are still being discovered; however, CBG shows promise in its positive effects across a wide range of conditions. Cannabigerol (CBG) is a non-psychotropic cannabinoid discovered in 1964 by Gaoni and Mechoulam (Gaoni, Mechoulam, 1964).
Many cell signal transduction pathways can be activated by CBG, explaining its wide effects across many conditions. Positive effects with the introduction of CBG have been shown in research for Huntington’s Disease, appetite-consumption levels, antibacterial efforts, and numerous other areas.
CBG has already been shown to improve motor skills and antioxidant defense levels in mice, inspiring Valedolivas et al. (2015) to further understand the neuroprotective capabilities of the cannabinoid.
The impact of breast cancer is seen highest in the female population, and is a condition still searching for the best therapeutic treatment. Cell death is commonly seen as an immune response to target tumor aggregates in breast cancer. This study looked specifically into the effect of CBG on two types of breast cancer cells (E3 luminal and EWD8 basal).
In order to determine if the CBG could affect the cells, primers were designed for genes that were hypothesized in previous research to respond to CBD….....
it appears that CBG slows proliferation and potentially induces necroptosis in human breast cancer cell lines.